Welcome to our dedicated page for Replimune Group SEC filings (Ticker: REPL), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Replimune Group, Inc. filings document regulatory, financing, governance and operating disclosures for a Nasdaq-listed clinical-stage biotechnology company focused on oncolytic immunotherapies. Recent Form 8-K reports cover FDA communications involving the RP1 Biologics License Application, including complete response letters and related Regulation FD disclosures.
The filing record also documents quarterly financial results, corporate presentation materials for RP1 and RP2 programs, amendments to the company’s loan and security agreement, and annual meeting voting results. These disclosures describe Replimune’s development-stage operating profile, capital structure arrangements, stockholder governance matters and material events tied to its cancer immunotherapy pipeline.
Replimune Group, Inc. (REPL) director Philip Astley-Sparke reported a bona fide gift of 50,000 shares of common stock on 2026-08-20, transferred to a donor-advised fund. The transaction carried a reported price of $0.00 per share and was classified as a disposition. Following the gift, Astley-Sparke directly holds 1,362,414 shares of Replimune common stock.
Replimune Group, Inc. (REPL) reported that its Chief Financial Officer, Emily Luisa Hill, sold 9,256 shares of common stock on 2026-08-17 at a weighted average price of $14.28 per share. The shares were sold to cover tax withholding obligations arising from the partial vesting of her Restricted Stock Units under an irrevocable "sell to cover" provision and are described as not a discretionary sale. Following this transaction, Hill directly holds 215,852 shares of Replimune common stock.
Replimune Group, Inc. has filed an automatic shelf registration statement on Form S-3, allowing it to offer, from time to time after effectiveness, an unspecified amount of common stock, preferred stock, debt securities, warrants and units. Specific terms, prices and amounts for each takedown will be detailed in future prospectus supplements.
The company is a commercial-stage biotechnology business focused on oncolytic immunotherapy, including its product TUDRIQEV and additional candidates from its RPx platform. As of August 11, 2026, authorized capital consists of 150 million common and 10 million preferred shares, with 93,798,096 common shares issued and outstanding, alongside multiple series of pre-funded warrants.
Net proceeds from any future offerings are expected to be used for general corporate purposes, which may include working capital, capital expenditures, investments in subsidiaries, acquisitions and repurchases or redemptions of securities. The filing also describes extensive anti-takeover and governance provisions under Delaware law and the company’s charter, as well as standard debt, warrant and unit structures that may be used in future financings.
Replimune Group, Inc. reported a quarterly net loss of $69.8 million for the three months ended June 30 2026, improving from $86.7 million a year earlier as total operating expenses declined to $68.2 million from $90.4 million, driven by lower research and development and selling, general and administrative costs.
Cash, cash equivalents and short‑term investments totaled $195.3 million at June 30 2026, supplemented by approximately $141.0 million in net proceeds from an August 2026 equity offering. The company states this liquidity, together with its plan, is expected to fund operations for more than 12 months, including commercialization of TUDRIQEV.
Subsequent to quarter end, the FDA granted accelerated approval for TUDRIQEV (vusolimogene oderparepvec‑wtpg) in combination with nivolumab for adults with unresectable advanced cutaneous melanoma progressing on anti‑PD‑1 therapy, and commercial launch is in progress. Long‑term debt under the Hercules facility stood at $84.1 million, with interest‑only payments and maturity now extended to October 1 2029.
Replimune Group, Inc. received an amended Schedule 13G from Ridgeback Capital entities updating their ownership in the company’s common stock. Ridgeback Capital Investments L.P., Ridgeback Capital Investments LLC and Ridgeback Capital Management LLC were previously reported as beneficially owning 7,310,656 shares, or 8.7% of the common stock outstanding, based on 83,945,161 shares outstanding as of June 25, 2026.
As of August 13, 2026, each Reporting Person now reports beneficial ownership of 2,912,373 shares of common stock, representing 3.5% of the outstanding shares, with shared voting and dispositive power over those shares. The filing indicates ownership of 5 percent or less of the class.
Replimune Group, Inc. reported fiscal first quarter 2027 results for the period ended June 30, 2026 and highlighted a transformational regulatory milestone. On August 6, 2026, the FDA granted accelerated approval for TUDRIQEV (vusolimogene oderparepvec-wtpg) in combination with nivolumab for adults with unresectable advanced cutaneous melanoma whose disease progressed on a PD‑1 antibody-based regimen. The company has started U.S. launch preparations and expects product to reach the market within 60 days.
Replimune also completed a $150 million financing to support the TUDRIQEV commercial launch and the IGNYTE‑3 confirmatory trial, and appointed Michelle DiNapoli as Chief Commercial Officer. For the quarter, total operating expenses were $68.2 million, down from $90.4 million a year earlier, leading to a net loss of $69.8 million versus $86.7 million. Cash, cash equivalents and short-term investments were $195.3 million as of June 30, 2026. The company states that existing cash, plus $141.0 million in net proceeds from an August 2026 common stock issuance, is expected to fund operations for more than twelve months, including commercialization of TUDRIQEV and general corporate purposes.
Replimune Group, Inc. director and Chief Executive Officer Sushil Patel reported a sale of 39,341 shares of common stock on 2026-08-10 at $12.97 per share. According to the disclosure, these shares were sold to cover tax withholding obligations arising from the vesting of performance-based restricted stock units under an irrevocable "sell to cover" provision and do not represent a discretionary sale. Following this transaction, Patel directly holds 708,151 shares of Replimune common stock.
Replimune Group, Inc. Chief Financial Officer Emily Luisa Hill reported a sale of 11,448 shares of common stock on 2026-08-10 at $12.97 per share. According to the disclosure, the shares were sold to cover tax withholding obligations upon vesting of performance-based RSUs and were executed under an irrevocable “sell to cover” provision, leaving her with 225,108 shares held directly.
Replimune Group, Inc. Chief Medical Officer Konstantinos Xynos reported a sale of 11,447 shares of common stock on 2026-08-10 at $12.97 per share. According to the disclosure, the shares were sold to cover tax withholding obligations upon vesting of performance-based RSUs under an irrevocable "sell to cover" provision and were not a discretionary sale. Following this transaction, Xynos directly holds 224,215 shares of Replimune common stock.
Replimune Group, Inc. Chief Accounting Officer Andrew Schwendenman reported a sale of 7,632 shares of common stock on 2026-08-10 at $12.97 per share. According to the company disclosure, the shares were sold solely to cover tax withholding obligations arising from the vesting of performance-based restricted stock units under an irrevocable “sell to cover” provision, and were not a discretionary sale. Following the transaction, Schwendenman directly holds 99,425 shares of Replimune common stock.